Cancer is comprised of many diseases, and we believe each cancer subtype should have its own targeted treatment. Stemcentrx has discovered and is developing drugs for a number of cancer subtypes. We are also developing companion diagnostic tests that can be used to identify those patients most likely to benefit from those drugs.
Stemcentrx has five investigational drugs in human clinical trials. As single agents, they have generated objective clinical responses in patients with small cell lung cancer, triple-negative breast cancer, ovarian cancer, and peritoneal cancer. Beyond these five clinical programs, we have a pipeline of additional novel targets to address other major cancer types.